Published in Antimicrob Agents Chemother on September 01, 1978
MK0787 (N-formimidoyl thienamycin): evaluation of in vitro and in vivo activities. Antimicrob Agents Chemother (1980) 9.02
In vitro activity of LY127935. Antimicrob Agents Chemother (1979) 7.01
Metabolism of thienamycin and related carbapenem antibiotics by the renal dipeptidase, dehydropeptidase. Antimicrob Agents Chemother (1982) 5.83
Thienamycin: new beta-lactam antibiotic with potent broad-spectrum activity. Antimicrob Agents Chemother (1979) 5.81
Antibacterial activities of a new stabilized thienamycin, N-formimidoyl thienamycin, in comparison with other antibiotics. Antimicrob Agents Chemother (1980) 5.47
Comparative in vitro activity of N-formimidoyl thienamycin against gram-positive and gram-negative aerobic and anaerobic species and its beta-lactamase stability. Antimicrob Agents Chemother (1982) 4.45
In vitro activity of N-formimidoyl thienamycin (MK0787). Antimicrob Agents Chemother (1980) 3.90
Inactivation of cephalosporins by Bacteroides. Antimicrob Agents Chemother (1979) 2.75
Comparative in vitro activity of new beta-lactam antibiotics against anaerobic bacteria. Antimicrob Agents Chemother (1981) 2.71
In vitro activity of N-formimidoyl thienamycin (MK0787), a crystalline derivative of thienamycin. Antimicrob Agents Chemother (1980) 2.68
Carbapenems: past, present, and future. Antimicrob Agents Chemother (2011) 2.61
Effect of N-formimidoyl thienamycin (MK0787) on beta-lactamases and activity against beta-lactamase-producing strains. Antimicrob Agents Chemother (1980) 2.53
In vitro activity of N-formimidoyl thienamycin (MK0787) against resistant strains of Pseudomonas aeruginosa, Staphylococcus epidermidis, Serratia marcescens, and Enterococcus spp. Antimicrob Agents Chemother (1981) 2.48
Influence of inoculum size on activity of cefoperazone, cefotaxime, moxalactam, piperacillin, and N-formimidoyl thienamycin (MK0787) against Pseudomonas aeruginosa. Antimicrob Agents Chemother (1980) 2.12
In vitro and pharmacokinetic properties of the carbapenems. Antimicrob Agents Chemother (1986) 1.50
A randomized comparison of cefoxitin with or without amikacin and clindamycin plus amikacin in surgical sepsis. Ann Surg (1981) 1.45
N-formimidoyl thienamycin (MK0787): in vitro study. Antimicrob Agents Chemother (1981) 1.26
Susceptibility of gram-positive cocci to various antibiotics, including cefotaxime, moxalactam, and N-formimidoyl thienamycin. Antimicrob Agents Chemother (1981) 1.09
In vitro comparison of N-formimidoyl thienamycin, piperacillin, cefotaxime, and cefoperazone. Antimicrob Agents Chemother (1981) 1.07
The evolving role of chemical synthesis in antibacterial drug discovery. Angew Chem Int Ed Engl (2014) 1.05
Imipenem-cilastatin as initial therapy for febrile cancer patients. Antimicrob Agents Chemother (1986) 1.05
Activity of N-formimidoyl thienamycin and cephalosporins against isolates from nosocomially acquired bacteremia. Antimicrob Agents Chemother (1982) 0.98
In vitro activity of MK0787 (N-formimidoyl thienamycin) and other beta-lactam compounds against Bacteroides spp. Antimicrob Agents Chemother (1981) 0.97
N-formimidoyl thienamycin (MK0787): in vitro activity against anaerobic bacteria. Antimicrob Agents Chemother (1982) 0.96
In vitro activity of N-formimidoyl thienamycin against 98 clinical isolates of Brucella melitensis compared with those of cefoxitin, rifampin, tetracycline, and co-trimoxazole. Antimicrob Agents Chemother (1982) 0.95
Pharmacokinetics of imipenem and cilastatin in patients with cystic fibrosis. Antimicrob Agents Chemother (1985) 0.86
Penem derivatives: beta-lactamase stability and affinity for penicillin-binding proteins in Escherichia coli. Antimicrob Agents Chemother (1982) 0.84
Stimulation of granulocyte functions in vitro by imipenem and the renal enzyme inhibitor MK 0791. Antimicrob Agents Chemother (1984) 0.82
Inhibition of transpeptidase activity in Escherichia coli by thienamycin. Antimicrob Agents Chemother (1979) 0.75
Susceptibility of anaerobic bacteria to 23 antimicrobial agents. Antimicrob Agents Chemother (1976) 9.53
Susceptibility of anaerobes to cefoxitin and other cephalosporins. Antimicrob Agents Chemother (1975) 8.86
Binding of thienamycin and clavulanic acid to the penicillin-binding proteins of Escherichia coli K-12. Antimicrob Agents Chemother (1977) 4.45
Activity of cefamandole and other cephalosporins against aerobic and anaerobic bacteria. Antimicrob Agents Chemother (1976) 4.07
Bacteroides fragilis resistant to the administration of clindamycin. Am J Med (1976) 3.13
Therapy for infections due to anaerobic bacteria: an overview. J Infect Dis (1977) 2.14
Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. N Engl J Med (1978) 14.65
Plasmid-controlled colonization factor associated with virulence in Esherichia coli enterotoxigenic for humans. Infect Immun (1975) 14.65
Production of vascular permeability factor by enterotoxigenic Escherichia coli isolated from man. Infect Immun (1973) 9.99
Susceptibility of anaerobes to cefoxitin and other cephalosporins. Antimicrob Agents Chemother (1975) 8.86
Anaerobic infections. 1. N Engl J Med (1974) 8.02
Enterotoxigenic Escherichia coli isolated from patients with severe cholera-like disease. J Infect Dis (1971) 7.10
In vitro activity of LY127935. Antimicrob Agents Chemother (1979) 7.01
Acute undifferentiated human diarrhea in the tropics. I. Alterations in intestinal micrflora. J Clin Invest (1971) 6.23
Toxigenic Escherichia coli: a cause of infantile diarrhea in Chicago. N Engl J Med (1972) 5.45
Cloning and sequencing of the class B beta-lactamase gene (ccrA) from Bacteroides fragilis TAL3636. Antimicrob Agents Chemother (1990) 5.24
Treating diarrhoea. BMJ (1997) 5.22
Travelers' diarrhea and toxigenic Escherichia coli. N Engl J Med (1975) 5.20
Polymyxin B-Induced Release of Low-Molecular-Weight, Heat-Labile Enterotoxin from Escherichia coli. Infect Immun (1974) 4.79
In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother (1999) 4.44
Activity of cefamandole and other cephalosporins against aerobic and anaerobic bacteria. Antimicrob Agents Chemother (1976) 4.07
Identification of enterotoxigenic Escherichia coli and serum antitoxin activity by the vascular permeability factor assay. Infect Immun (1973) 4.07
Clindamycin-induced enterocolitis in hamsters as a model of pseudomembranous colitis in patients. Infect Immun (1978) 3.93
Experimental intra-abdominal abscesses in rats: development of an experimental model. Infect Immun (1974) 3.91
In vitro activity of N-formimidoyl thienamycin (MK0787). Antimicrob Agents Chemother (1980) 3.90
Beta-lactamase-mediated imipenem resistance in Bacteroides fragilis. Antimicrob Agents Chemother (1986) 3.87
Intestinal microflora. Gastroenterology (1971) 3.86
Intestinal flora in health and disease. Gastroenterology (1984) 3.84
Susceptibility of the Bacteroides fragilis group in the United States in 1981. Antimicrob Agents Chemother (1983) 3.83
Studies of intestinal microflora. II. Microorganisms of the small intestine and their relations to oral and fecal flora. Gastroenterology (1967) 3.71
Management of anaerobic infections. Ann Intern Med (1975) 3.62
Metronidazole versus anaerobes. In vitro data and initial clinical observations. Calif Med (1972) 3.62
Studies of intestinal microflora. I. Effects of diet, age, and periodic sampling on numbers of fecal microorganisms in man. Gastroenterology (1967) 3.60
Rapid diagnosis of anaerobic infections by direct gas-liquid chromatography of clinical speciments. J Clin Invest (1976) 3.34
Microbial synergy in experimental intra-abdominal abscess. Infect Immun (1976) 3.21
Abdominal trauma, anaerobes, and antibiotics. Surg Gynecol Obstet (1973) 3.18
Anaerobic infections (second of three parts). N Engl J Med (1974) 3.18
Anaerobic infections (third of three parts). N Engl J Med (1974) 3.13
Bacteroides fragilis resistant to the administration of clindamycin. Am J Med (1976) 3.13
In vitro and in vivo antibacterial activities of the glycylcyclines, a new class of semisynthetic tetracyclines. Antimicrob Agents Chemother (1993) 3.13
Intestinal fluid and electrolyte transport in human cholera. J Clin Invest (1970) 3.09
Studies on enterotoxin from Escherichia coli associated with acute diarrhea in man. J Lab Clin Med (1971) 3.03
Characterization of pBFTM10, a clindamycin-erythromycin resistance transfer factor from Bacteroides fragilis. J Bacteriol (1982) 2.80
Survival of Lactobacillus species (strain GG) in human gastrointestinal tract. Dig Dis Sci (1992) 2.78
Oxygen tolerance of fresh clinical anaerobic bacteria. J Clin Microbiol (1975) 2.77
Inactivation of cephalosporins by Bacteroides. Antimicrob Agents Chemother (1979) 2.75
Pseudomembranous enterocolitis (antibiotic-related colitis). Adv Intern Med (1977) 2.73
Antimicrobial susceptibilities of 1,292 isolates of the Bacteroides fragilis group in the United States: comparison of 1981 with 1982. Antimicrob Agents Chemother (1984) 2.71
In vitro activity of azthreonam, a monobactam antibiotic. Antimicrob Agents Chemother (1982) 2.70
Cefoxitin inactivation by Bacteroides fragilis. Antimicrob Agents Chemother (1983) 2.64
Hormone levels during dietary changes in premenopausal African-American women. J Natl Cancer Inst (1996) 2.59
Effect of preoperative neomycin-erythromycin intestinal preparation on the incidence of infectious complications following colon surgery. Ann Surg (1973) 2.57
Antimicrobial therapy of experimental intraabdominal sepsis. J Infect Dis (1975) 2.56
Stimulation of intestinal adenyl cyclase by Escherichia coli enterotoxin: comparison of strains from an infant and an adult with diarrhea. J Infect Dis (1974) 2.52
Tn4400, a compound transposon isolated from Bacteroides fragilis, functions in Escherichia coli. J Bacteriol (1985) 2.48
Nationwide study of the susceptibility of the Bacteroides fragilis group in the United States. Antimicrob Agents Chemother (1985) 2.47
Mechanisms of drug-resistance transfer in Bacteroides fragilis. J Antimicrob Chemother (1981) 2.46
Susceptibility of the Bacteroides fragilis group in the United States: analysis by site of isolation. Antimicrob Agents Chemother (1988) 2.45
Neutralization of Clostridium difficile toxin by Clostridium sordellii antitoxins. Infect Immun (1978) 2.39
Plasmid-mediated, transferable resistance to clindamycin and erythromycin in Bacteroides fragilis. J Infect Dis (1979) 2.38
Preoperative oral antibiotics reduce septic complications of colon operations: results of prospective, randomized, double-blind clinical study. Ann Surg (1977) 2.36
Experimental intra-abdominal abscesses in rats: quantitative bacteriology of infected animals. Infect Immun (1974) 2.33
Rapid microbiological assay for chloramphenicol and tetracyclines. Antimicrob Agents Chemother (1976) 2.26
Antimicrobial substance from a human Lactobacillus strain. Antimicrob Agents Chemother (1987) 2.25
Acute undifferentiated human diarrhea in the tropics. II. Alterations in intestinal fluid and electrolyte movements. J Clin Invest (1971) 2.22
Treatment of anaerobic infections with metronidazole. Antimicrob Agents Chemother (1975) 2.21
Survival of lactic acid bacteria in the human stomach and adhesion to intestinal cells. J Dairy Sci (1987) 2.17
Anaerobic infections of the female genital tract: bacteriologic and therapeutic aspects. Am J Obstet Gynecol (1973) 2.07
The human intestinal microflora. Dig Dis Sci (1986) 2.07
Once-daily dosing in dogs optimizes daptomycin safety. Antimicrob Agents Chemother (2000) 2.00
Bacteriology of empyema. Lancet (1974) 2.00
National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004. Antimicrob Agents Chemother (2007) 1.95
Mechanisms of resistance and resistance transfer in anaerobic bacteria: factors influencing antimicrobial therapy. Rev Infect Dis (1984) 1.94
Glycylcyclines. 1. A new generation of potent antibacterial agents through modification of 9-aminotetracyclines. J Med Chem (1994) 1.93
Efficacy of preoperative antimicrobial preparation of the bowel. Ann Surg (1972) 1.88
Successful treatment of relapsing Clostridium difficile colitis with Lactobacillus GG. Lancet (1987) 1.88
Anaerobes survive in clinical specimens despite delayed processing. J Clin Microbiol (1976) 1.87
Purification of Shigella dysenteriae 1 (Shiga)-like toxin from Escherichia coli O157:H7 strain associated with haemorrhagic colitis. Lancet (1983) 1.87
Estrogen metabolism and excretion in Oriental and Caucasian women. J Natl Cancer Inst (1994) 1.85
Antimicrobial use in animal feed--time to stop. N Engl J Med (2001) 1.84
Comparative In vitro activities of daptomycin and vancomycin against resistant gram-positive pathogens. Antimicrob Agents Chemother (2000) 1.84
Attachment pili from enterotoxigenic Escherichia coli pathogenic for humans. Infect Immun (1979) 1.80
Studies of intestinal microflora. V. Fecal microbial ecology in ulcerative colitis and regional enteritis: relationship to severity of disease and chemotherapy. Gastroenterology (1968) 1.80
Hybridization studies reveal homologies between pBF4 and pBFTM10, Two clindamycin-erythromycin resistance transfer plasmids of Bacteroides fragilis. J Bacteriol (1982) 1.79